Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / PHARMACEUTCL ETF
-
Total 13F shares
-
1,560,345
-
Share change
-
-339,207
-
Total reported value
-
$85,525,178
-
Put/Call ratio
-
0%
-
Price per share
-
$54.79
-
Number of holders
-
42
-
Value change
-
-$19,786,334
-
Number of buys
-
15
-
Number of sells
-
22
Institutional Holders of VANECK ETF TRUST - PHARMACEUTCL ETF (PPH) as of Q4 2018
As of 31 Dec 2018,
VANECK ETF TRUST - PHARMACEUTCL ETF (PPH) was held by
42 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,560,345 shares.
The largest 10 holders included
GOLDMAN SACHS GROUP INC, MEITAV DASH INVESTMENTS LTD, CLS Investments, LLC, CITADEL ADVISORS LLC, BANK OF AMERICA CORP /DE/, MORGAN STANLEY, Cerity Partners LLC, ROYAL BANK OF CANADA, LPL Financial LLC, and OPPENHEIMER & CO INC.
This page lists
42
institutional shareholders reporting positions in this security
for the Q4 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.